Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01564316
Recruitment Status : Terminated (The study has been terminated due to difficulties in gathering the patient samples.)
First Posted : March 27, 2012
Last Update Posted : April 15, 2016
Sponsor:
Information provided by (Responsible Party):
Seoul National University Hospital

Brief Summary:
Using to method of Proteomics, for aims to conquer intractable disease, try to access variety experiment. Biomarker is necessary to develop new diagnosis method and target of treatment.

Condition or disease
Biomarker With Neurodegeneration Patients

Detailed Description:
Following Seoul National University Hospital Institutional Review Board approval, obtain serum and platelet with neurodegeneration patients and control group visited the part of neurology, there'll be analysis to differentiate each other diseases use to method Proteomics. Biomarker will be screening via 1D/2D analysis, Mass analysis, database searching- the MASCOT search tool, SWISS-PROT and etc.

Layout table for study information
Study Type : Observational
Actual Enrollment : 22 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Proteomics Study by Serum and Platelet With Neurodegeneration Disease Patients
Study Start Date : May 2005
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Group/Cohort
neurodegeneration patients
•neurodegeneration patients and control group include dementia patients visited the part of neurology



Biospecimen Retention:   Samples With DNA

serum:10ml

WHO: neurodegeneration patients and control group include dementia patients visited the part of neurology.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

neurodegeneration patients group include dementia patients visited the part of neurology.

(almost after diagnosis)

Criteria

Inclusion Criteria:

  • neurodegeneration patients and control group include dementia patients visited the part of neurology.
  • over the age of 18
  • when participants can understand subject of this study
  • Total point of Mini Mental state exam(MMSE)should be Under 26 include MCI (mild cognitive impairment) and over GDS score 3points.

exclusion criteria:

  • under eighteen years of age
  • when participants cannot understand subject of this study
  • cannot accept this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01564316


Locations
Layout table for location information
Korea, Republic of
Department of Neurology, Seoul National University Hospital
Seoul, Korea, Republic of, 110744
Sponsors and Collaborators
Seoul National University Hospital
Investigators
Layout table for investigator information
Study Director: Manho Kim, Professor Seoul National University Hospital
Layout table for additonal information
Responsible Party: Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01564316    
Other Study ID Numbers: H-0505-148-016
First Posted: March 27, 2012    Key Record Dates
Last Update Posted: April 15, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Nerve Degeneration
Pathologic Processes